Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer

British Journal of Pharmacology

Volumn 169, Issue 8, 2013, Pages 1745-1765

  Curtin, N J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

cancer; DNA damage signalling and repair; synthetic lethality

Indexed keywords

'7 NITROINDOLE 2 CARBOXYLIC ACID; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 AMINOBENZAMIDE; 7 NITROINDOLE 2 CARBOXYLIC ACID; 8 HYDROXY 2 METHYL 4(3H) QUINAZOLINONE; CAPECITABINE; CELL DNA; CRT 0044876; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; INO 1001; ISOQUINOLINONE DERIVATIVE; LOMEGUATRIB; LOMUSTINE; LUCANTHONE; NAVELBINE; NERATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PEMETREXED; QUINAZOLINONE DERIVATIVE; RUCAPARIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE ARREST; CELL DEATH; CELL VIABILITY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; COLON CANCER; DAUGHTER CELL; DNA DAMAGE; DNA DAMAGE RESPONSE; DNA END JOINING REPAIR; DNA REPAIR; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; EXCISION REPAIR; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TREATMENT RESPONSE; UPREGULATION;

CANCER; DNA DAMAGE SIGNALLING AND REPAIR; SYNTHETIC LETHALITY;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE CHECKPOINTS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; UP-REGULATION;

EID: 84881357858     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12244     Document Type: Review

References (228)

1. Abbotts R, Madhusudan S, (2010). Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev 36: 425-435.
2. Ahnesorg P, Smith P, Jackson SP, (2006). XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell 124: 301-313.
3. Ai L, Vo QN, Zuo C, Li L, Ling W, Suen JY, et al. (2004). Ataxia-telangiectasia-mutated (ATM) gene in head and neck squamous cell carcinoma: promoter hypermethylation with clinical correlation in 100 cases. Cancer Epidemiol Biomarkers Prev 13: 150-156.
4. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, et al. (2007). Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models. Clin Cancer Res 13: 3033-3042.
5. Ali M, Telfer BA, McCrudden C, O'Rourke M, Thomas HD, Kamjoo M, et al. (2009). Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? Clin Cancer Res 15: 6106-6112.
6. Ali M, Kamjoo M, Thomas HD, Kyle S, Pavlovska I, Barbur M, et al. (2011). The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumour perfusion and radiation response in mice. Mol Can Ther 10: 2320-2329.
7. Allen C, Halbrook J, Nickoloff JA, (2003). Interactive competition between homologous recombination and non-homologous end joining. Mol Cancer Res 1: 913-920.
8. Almeida KH, Sobol RW, (2007). A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair (Amst) 6: 695-711.
9. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251.
10. Ayi TC, Loh KC, Ali RB, Li BF, (1992). Intracellular localization of human DNA repair enzyme methylguanine-DNA methyltransferase by antibodies and its importance. Cancer Res 52: 6423-6430.
11. Banasik M, Komura H, Shimoyama M, Ueda K, (1992). Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267: 1569-1575.
12. Bapat A, Glass LS, Luo M, Fishel ML, Long EC, Georgiadis MM, et al. (2010). Novel small molecule inhibitor of Ape1 endonuclease blocks proliferation and reduces viability of glioblastoma cells. J Pharmacol Exp Ther 334: 988-998.
13. Barreto-Andrade JC, Efimova EV, Mauceri HJ, Beckett MA, Sutton HG, Darga TE, et al. (2011). Response of human prostate cancer cells and tumors to combining PARP inhibition with ionizing radiation. Mol Cancer Ther 10: 1185-1193.
14. Barrow E, Alduaij W, Robinson L, Shenton A, Clancy T, Lalloo F, et al. (2008). Colorectal cancer in HNPCC: cumulative lifetime incidence, survival and tumour distribution. A report of 121 families with proven mutations. Clin Genet 74: 233-242.
15. Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebaek NE, et al. (2007). DNA damage response mediators MDC1 and 53BP1: constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 26: 7414-7422.
16. Bedikian AY, Papadopoulos NE, Kim KB, Hwu WJ, Homsi J, Glass MR, et al. (2009). A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Invest 27: 756-763.
17. Ben-Hur E, Chen CC, Elkind MM, (1985). Inhibitors of poly(adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res 45: 2123-2127.
18. Berman DB, Costalas J, Schultz DC, Grana G, Daly M, Godwin AK, (1996). A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 56: 3409-3414.
19. Bindra RS, Schaffer PJ, Meng A, Woo J, Måseide K, Roth ME, et al. (2005). Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability. Ann N Y Acad Sci 1059: 184-195.
20. Bolderson E, Tomimatsu N, Richard DJ, Boucher D, Kumar R, Pandita TK, et al. (2010). Phosphorylation of Exo1 modulates homologous recombination repair of DNA double-strand breaks. Nucleic Acids Res 38: 1821-1831.
21. Boulton S, Kyle S, Durkacz BW, (2000). Mechanisms of enhancement of cytotoxicity in etoposide and ionising radiation-treated cells by the protein kinase inhibitor wortmannin. Eur J Cancer 36: 535-541.
22. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, Van Der Gulden H, et al. (2010). 53bp1 loss rescues Brca1 deficiency and is associated with triple-negative and Brca-mutated breast cancers. Nat Struct Mol Biol 17: 688-695.
23. Bowman KJ, White A, Golding BT, Griffin RJ, Curtin NJ, (1998). Potentiation of anticancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors, NU1025 and NU1064. Br J Cancer 78: 1269-1277.
24. Bowman KJ, Newell DR, Calvert AH, Curtin NJ, (2001). Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro. Br J Cancer 84: 106-112.
25. Brock WA, Milas L, Bergh S, Lo R, Szabo C, Mason KA, (2004). Radiosensitization of human and rodent cell lines by INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase. Cancer Lett 205: 155-160.
26. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL, (2002). Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 94: 1365-1372.
27. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose)polymerase. Nature 434: 913-917.
28. Bugreev DV, Brosh RM Jr, Mazin AV, (2008). RECQ1 possesses DNA branch migration activity. J Biol Chem 283: 20231-20242.
29. Bulgar AD, Weeks LD, Miao Y, Yang S, Xu Y, Guo C, Markowitz S, et al. (2012). Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair. Cell Death Dis 3: e252.
30. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, et al. (2010). 53bp1 inhibits homologous recombination in brca1-deficient cells by blocking resection of DNA breaks. Cell 141: 243-254.
31. Burma S, Chen BPC, Chen DJ, (2006). Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair (Amst) 5: 1042-1048.
32. Butturini A, Gale RP, Verlander PC, Adler-Brecher B, Gillio AP, Auerbach AD, (1994). Hematologic abnormalities in Fanconi anemia: an International Fanconi Anemia Registry study. Blood 84: 1650-1655.
33. Calabrese CR, Batey MA, Thomas HD, Durkacz BD, Wang L-Z, Kyle S, et al. (2003). Identification of potent non-toxic poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors: chemopotentiation and pharmacological studies. Clin Cancer Res 9: 2711-2718.
34. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, et al. (2004). Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP-1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J Natl Cancer Inst 96: 56-67.
35. Canan Koch SS, Thoresen LH, Tikhe JG, Maegley KA, Almassy RJ, Li J, et al. (2002). Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray co-crystal structure. J Med Chem 45: 4961-4974.
36. Caporali S, Falcinelli S, Starace G, Russo MT, Bonmassar E, Jiricny J, et al. (2004). DNA damage induced by temozolomide signals to both ATM and ATR: role of mismatch repair system. Mol Pharmacol 66: 478-491.
37. Carrassa L, Broggini M, Erba E, Damia G, (2004). Chk1, but not Chk2, is involved in the cellular response to DNA damaging agents: differential activity in cells expressing or not p53. Cell Cycle 3: 1177-1181.
38. Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. (2008). Chronic hypoxia decreases synthesis of homologous recombination proteins to offset chemoresistance and radioresistance. Cancer Res 68: 605-614.
39. Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, et al. (2010). Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res 70: 8045-8054.
40. Charrier JD, Durrant SJ, Golec JM, Kay DP, Knegtel RM, MacCormick S, et al. (2011). Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents. J Med Chem 54: 2320-2330.
41. Cheng CL, Johnson SP, Keir ST, Quinn JA, Ali-Osman F, Szabo C, et al. (2005). Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. Mol Cancer Ther 4: 1364-1368.
42. Choi S, Gamper AM, White JS, Bakkenist CJ, (2010). Inhibition of ATM kinase activity does not phenocopy ATM protein disruption: implications for the clinical utility of ATM kinase inhibitors. Cell Cycle 9: 4052-4057.
43. Choudhury A, Zhao H, Jalali F, Al Rashid S, Ran J, Supiot S, et al. (2009). Targeting homologous recombination using imatinib results in enhanced tumor cell chemosensitivity and radiosensitivity. Mol Cancer Ther 8: 203-213.
44. Cimprich KA, Cortez D, (2008). ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9: 616-627.
45. Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA, et al. (2009). Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther 8: 407-414.
46. Cliby WA, Roberts CJ, Cimprich KA, Stringer CM, Lamb JR, Schreiber SL, et al. (1998). Overexpression of a kinase-inactive ATR protein causes sensitivity to DNA damaging agents and defects in cell cycle checkpoints. EMBO J 17: 159-169.
47. Cortez D, Wang Y, Qin J, Elledge SJ, (1999). Requirement of ATM dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. Science 286: 1162-1166.
48. Cox LS, Lane DP, Abbondandolo A, Dogliotti E, (1996). Two pathways for base excision repair in mammalian cells. J Biol Chem 271: 9573-9578.
49. Curtin NJ, (2005). PARP inhibitors for cancer therapy. Expert Rev Mol Med 7: 1-20.
50. Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, et al. (2004). Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells. Clin Cancer Res 10: 881-889.
51. Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, et al. (2009). Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 15: 1241-1249.
52. Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, et al. (2010). Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG014699. Br J Cancer 103: 1588-1596.
53. Dedon PC, Jiang ZW, Goldberg IH, (1992). Neocarzinostatin-mediated DNA damage in a model AGT.ACT site: mechanistic studies of thiol-sensitive partitioning of C4' DNA damage products. Biochemistry 31: 1917-1927.
54. Del Rowe JD, Bello J, Mitnick R, Sood B, Filippi C, Moran J, et al. (1999). Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radiat Oncol Biol Phys 43: 89-93.
55. Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, et al. (2000). Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin Cancer Res 6: 2860-2867.
56. Demple B, Sung JS, (2005). Molecular and biological roles of Ape1 protein in mammalian base excision repair. DNA Repair (Amst) 4: 1442-1449.
57. Derheimer FA, Kastan MB, (2010). Multiple roles of ATM in monitoring and maintaining DNA integrity. FEBS Lett 584: 3675-3681.
58. Di Virgilio M, Ying CY, Gautier J, (2009). PIKK-dependent phosphorylation of Mre11 induces MRN complex inactivation by disassembly from chromatin. DNA Repair (Amst) 8: 1311-1320.
59. Digweed M, Sperling K, (2004). Nijmegen breakage syndrome: clinical manifestation of defective response to DNA double-strand breaks. DNA Repair (Amst) 3: 1207-1217.
60. Dobrovic A, Simpfendorfer D, (1997). Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 57: 3347-3350.
61. Dolan ME, Moschel RC, Pegg AE, (1990). Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 87: 5368-5372.
62. Dolan ME, Roy SK, Fasanmade A, Paras PR, Schilsky RL, Ratain MJ, (1998). O6-Benzylguanine in humans: metabolic, pharmacokinetic and pharmacodynamic findings. J Clin Oncol 16: 1803-1810.
63. Donawho CK, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, et al. (2007). ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 13: 2728-2737.
64. Drew Y, Mulligan EA, Vong W-T, Thomas HD, Kahn S, Kyle S, et al. (2011a). Therapeutic potential of PARP inhibitor AG014699 in human cancer with mutated or methylated BRCA. J Natl Cancer Inst 103: 334-346.
65. Drew Y, Ledermann JA, Jones A, Hall G, Jayson GC, Highley M, et al. (2011b). Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2-mutated, advanced ovarian and/or locally advanced or metastatic breast cancer. J Clin Oncol 29: 2011 (suppl; abstr 3104).
66. Dungey FA, Loser DA, Chalmers AJ, (2008). Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 72: 1188-1197.
67. Dupré A, Boyer-Chatenet L, Sattler RM, Modi AP, Lee JH, Nicolette ML, et al. (2008). A forward chemical genetic screen reveals an inhibitor of the Mre11-Rad50-Nbs1 complex. Nat Chem Biol 4: 119-125.
68. Durkacz BW, Omidiji O, Gray DA, Shall S, (1980). (ADP-ribose)n participates in DNA excision repair. Nature 283: 593-596.
69. Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. (2008). Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451: 1111-1115.
70. El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW, (2003). A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res 31: 5526-5533.
71. Elliott SL, Crawford C, Mulligan E, Summerfield G, Newton P, Wallis J, et al. (2011). Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia. Br J Haematol 152: 61-71.
72. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. (2000). Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92: 564-569.
73. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434: 917-921.
74. Ferraris DV, (2010). Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic. J Med Chem 53: 4561-4584.
75. Fishel ML, Kelley MR, (2007). The DNA base excision repair protein Ape1/Ref-1 as a therapeutic and chemopreventive target. Mol Aspects Med 28: 375-395.
76. Fishel ML, He Y, Smith ML, Kelley MR, (2007). Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin Cancer Res 13: 260-267.
77. Flanagan JM, Munoz-Alegre M, Henderson S, Tang T, Sun P, Johnson N, et al. (2009). Gene-body hypermethylation of ATM in peripheral blood DNA of bilateral breast cancer patients. Hum Mol Genet 18: 1332-1342.
78. Flynn RL, Zou LATR, (2011). ATR: A master conductor of cellular responses to DNA replication stress. Trends Biochem Sci 36: 133-140.
79. Fokas E, Prevo R, Pollard JR, Reaper PM, Charlton PA, Cornelissen B, et al. (2012). Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis 3: e441.
80. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. (2009a). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
81. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, et al. (2009b). Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28: 2512-2519.
82. Fraser M, Zhao H, Luoto KR, Lundin C, Coackley CL, Chan N, et al. (2012). PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res 18: 1015-1027.
83. Friedman HS, Kokkinakis DM, Pluda J, Friedman AH, Cokgor I, Haglund MM, et al. (1998). Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. J Clin Oncol 16: 3570-3575.
84. Gari K, Decaillet C, Stasiak AZ, Stasiak A, Constantinou A, (2008). The Fanconi anemia protein FANCM can promote branch migration of Holliday junctions and replication forks. Mol Cell 29: 141-148.
85. Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. (2011). Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12: 852-861.
86. Gerson SL, (2004). MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 4: 296-307.
87. Giannini G, Ristori E, Cerignoli F, Rinaldi C, Zani M, Viel A, et al. (2002). Human MRE11 is inactivated in mismatch repair-deficient cancers. EMBO Rep 3: 248-254.
88. Golding SE, Rosenberg E, Valerie N, Hussaini I, Frigerio M, Cockcroft XF, et al. (2009). Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol Cancer Ther 8: 2894-2902.
89. Griffin RJ, Pemberton LC, Rhodes D, Bleasdale C, Bowman K, Calvert AH, et al. (1995). Novel potent inhibitors of the DNA repair enzyme poly(ADP-ribose)polymerase (PARP). Anticancer Drug Des 10: 507-514.
90. Hanahan D, Weinberg RA, (2011). Hallmarks of cancer: the next generation. Cell 144: 646-674.
91. Hardcastle IR, Cockcroft X, Curtin NJ, El-Murr MD, Leahy JJ, Stockley M, et al. (2005). Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a small-molecule library approach. J Med Chem 48: 7829-7846.
92. Harper JV, Anderson JA, O'Neill P, (2010). Radiation induced DNA DSBs: contribution from stalled replication forks? DNA Repair (Amst) 9: 907-913.
93. Heikkinen K, Karppinen SM, Soini Y, Makinen M, Winqvist R, (2003). Mutation screening of Mre11 complex genes: indication of RAD50 involvement in breast and ovarian cancer susceptibility. J Med Genet 40: e131.
94. Heyer WD, Li X, Rolfsmeier M, Zhang XP, (2006). Rad54: the Swiss Army knife of homologous recombination? Nucleic Acids Res 34: 4115-4125.
95. Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin MNB, Orr AI, et al. (2004). Identification of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64: 9152-9159.
96. Hollick JJ, Rigoreau LJM, Cano-Soumillac C, Cockcroft X, Curtin NJ, Frigerio M, et al. (2007). Pyranone, thiopyranone, and pyridone inhibitors of phosphatidylinositol 3-kinase related kinases. Structure-activity relationships for DNA-dependent protein kinase inhibition, and identification of the first potent and selective inhibitor of the ataxia telangiectasia mutated kinase. J Med Chem 50: 1958-1972.
97. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, et al. (2009). Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 8: 2232-2242.
98. Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL, Mazin AV, (2011). Identification of specific inhibitors of human RAD51 recombinase using high-throughput screening. ACS Chem Biol 6: 628-635.
99. Ibrahim YH, García-García C, Serra V, He L, Torres-Lockhart K, Prat A, et al. (2012). PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2: 1036-1047.
100. Ip SC, Rass U, Blanco MG, Flynn HR, Skehel JM, West SC, (2008). Identification of Holliday junction resolvases from humans and yeast. Nature 456: 357-361.
101. Ismail IH, Martensson S, Moshinsky D, Rice A, Tang C, Howlett A, et al. (2004). SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene 23: 873-882.
102. Izzard RA, Jackson SP, Smith GC, (1999). Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res 59: 2581-2586.
103. Jacq X, Smith L, Brown E, Hughes A, Odedra R, Heathcote D, et al. (2012). AZ20, a novel potent and selective inhibitor of ATR kinase with in vivo antitumour activity. Cancer Res 72 (8 Suppl. 1): Abstract nr 1823.
104. Jagtap P, Szabo C, (2005). Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4: 421-440.
105. Javle M, Curtin NJ, (2011). The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 105: 1114-1122.
106. Jeggo PA, Caldecott K, Pidsley S, Banks GR, (1989). Sensitivity of Chinese hamster ovary mutants defective in DNA double strand break repair to topoisomerase II inhibitors. Cancer Res 49: 7057-7063.
107. Jensen RB, Carreira A, Kowalczykowski SC, (2010). Purified human BRCA2 stimulates RAD51-mediated recombination. Nature 467: 678-683.
108. Johnson N, Li Y-C, Walton ZE, Cheng KA, Li D, Rodig SJ, et al. (2011). Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 17: 875-883.
109. Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmañà J, et al. (2012). Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2: 1048-1063.
110. Kashishian A, Douangpanya H, Clark D, Schlachter ST, Eary CT, Schiro JG, et al. (2003). DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol Cancer Ther 2: 1257-1264.
111. Kefford RF, Thomas NP, Corrie PG, Palmer C, Abdi E, Kotasek D, et al. (2009). A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. Br J Cancer 100: 1245-1249.
112. Khan K, Araki K, Wang D, Li G, Li X, Zhang J, et al. (2010). Head and neck cancer radiosensitization by the novel poly(ADP-ribose) polymerase inhibitor GPI-15427. Head Neck 32: 381-391.
113. Khan OA, Ranson M, Michael M, Olver I, Levitt NC, Mortimer P, et al. (2008). A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 98: 1614-1618.
114. Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, et al. (2011). A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer 104: 750-755.
115. Kim NG, Choi YR, Baek MJ, Kim YH, Kang H, Kim NK, et al. (2001). Frameshift mutations at coding mononucleotide repeats of the hRAD50 gene in gastrointestinal carcinomas with microsatellite instability. Cancer Res 61: 36-38.
116. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, Williams O, et al. (2006). A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell 125: 733-747.
117. Kruszewski M, Wojewodzka M, Iwanenko T, Szumiel I, Okuyama A, (1998). Differential inhibitory effect of OK-1035 on DNA repair in L5178Y murine lymphoma sublines with functional or defective repair of double strand breaks. Mutat Res 409: 31-36.
118. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. (2011). Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 71: 5626-5634.
119. Kurimasa A, Kumano S, Boubnov NV, Story MD, Tung CS, Peterson SR, et al. (1999). Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. Mol Cell Biol 19: 3877-3884.
120. Lahtz C, Pfeifer GP, (2011). Epigenetic changes of DNA repair genes in cancer. J Mol Cell Biol 3: 51-58.
121. Leahy JJ, Golding BT, Griffin RJ, Hardcastle IR, Richardson C, Rigoreau L, et al. (2004). Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg Med Chem Lett 14: 6083-6087.
122. Lee MN, Tseng RC, Hsu HS, et al. (2007). Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. Clin Cancer Res 13: 832-838.
123. Lees-Miller SP, Meek K, (2003). Repair of DNA double strand breaks by non-homologous end joining. Biochimie 85: 1161-1173.
124. Leopold WR, Sebolt-Leopold JS, (1992). Chemical approaches to improved radiotherapy. In:, Valeriote FA, Corbett TH, Baker LH, (eds). Cytotoxic Anticancer Drugs: Models and Concepts for Drug Discovery and Development. Kluwer: Boston, MA, pp. 179-196.
125. Lindahl T, (1993). Instability and decay of the primary structure of DNA. Nature 362: 709-715.
126. Liu J, Doty T, Gibson B, Heyer WD, (2010). Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat Struct Mol Biol 17: 1260-1262.
127. Liu L, Nakatsuru Y, Gerson SL, (2002). Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 8: 2985-2991.
128. Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, et al. (2008). Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks. Mol Cancer Res 6: 1621-1629.
129. Liu Y, Tarsounas M, O'Regan P, West SC, (2007). Role of RAD51C and XRCC3 in genetic recombination and DNA repair. J Biol Chem 282: 1973-1979.
130. Lord CJ, MacDonald S, Swift S, Turner NC, Ashworth A, (2008). A high-throughput RNA interference screen for DNA repair determinants of PARP inhibitor sensitivity. DNA Repair (Amst) 7: 2010-2019.
131. LoRusso P, Ji JJ, Li J, Heilbrun LK, Shapiro G, Sausville EA, et al. (2011). Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888; V) in combination with irinotecan (CPT-11; Ir) in patients (pts) with advanced solid tumors. J Clin Oncol 29 (15 Suppl.): 3000.
132. Luo M, Kelley MR, (2004). Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res 24: 2127-2134.
133. Lynch HT, de la Chapelle A, (1999). Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet 36: 801-818.
134. McCabe N, Turner NC, Lord CJ, Kluzek K, Bialkowska A, Swift S, et al. (2006). Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 66: 8109-8115.
135. McClendon AK, Osheroff N, (2007). DNA topoisomerase II, genotoxicity, cancer. Mutat Res 623: 83-97.
136. McElhinney RS, McMurry TB, Margison GP, (2003). O6-alkylguanine-DNA alkyltransferase inactivation in cancer chemotherapy. Mini Rev Med Chem 3: 471-485.
137. Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, Houlbrook S, et al. (2005). Isolation of a small molecule inhibitor of DNA base excision repair. Nucleic Acids Res 33: 4711-4724.
138. Mahaney BL, Meek K, Lees-Miller SP, (2009). Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem J 417: 639-650.
139. Malanga M, Althaus FR, (2004). Poly(ADP-ribose) reactivates stalled DNA topoisomerase I and Induces DNA strand break resealing. J Biol Chem 279: 5244-5248.
140. Massague J, (2004). G1 cell cycle control and cancer. Nature 432: 298-306.
141. Mehta MP, Curran WJ, Wang D, Wang F, Kleinberg L, Brade AM, et al. (2012). Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases. J Clin Oncol 30 Suppl; abstr 2013.
142. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. (2009). Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 1: 315-322.
143. Menear KA, Adcock C, Boulter R, Cockcroft XL, Copsey L, Cranston A, et al. (2008). 4-[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]- 2H-phthalazin-1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 51: 6581-6591.
144. Merkle D, Douglas P, Moorhead GB, Leonenko Z, Yu Y, Cramb D, et al. (2002). The DNA-dependent protein kinase interacts with DNA to form a protein-DNA complex that is disrupted by phosphorylation. Biochemistry 41: 12706-12714.
145. Middleton MR, Kelly J, Thatcher N, Donnelly DJ, McElhinney RS, McMurry TB, et al. (2000). O(6)-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 85: 248-252.
146. Miknyoczki SJ, Jones-Bolin S, Pritchard S, Hunter K, Zhao H, Wan W, et al. (2003). Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol Cancer Ther 2: 371-382.
147. Mitchell J, Smith GCM, Curtin NJ, (2009). Poly(ADP-ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double strand break repair following ionising radiation. Int J Radiat Oncol Biol Phys 75: 1520-1527.
148. Munck JM, Batey MA, Zhao Y, Jenkins H, Richardson CJ, Cano C, et al. (2012). Chemosensitization of cancer cells by KU-0060648, a dual inhibitor of DNA-PK and PI-3K. Mol Cancer Ther 11: 1789-1798.
149. de Murcia G, Ménissier de Murcia J, (1994). Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 19: 172-176.
150. 1 checkpoint-deficient cells to lethal premature chromatin condensation. Proc Natl Acad Sci U S A 98: 9092-9097.
151. Nikjoo H, O'Neill P, Wilson WE, Goodhead DT, (2001). Computational approach for determining the spectrum of DNA damage induced by ionizing radiation. Radiat Res 156: 577-583.
152. Nishida H, Tatewaki N, Nakajima Y, Magara T, Ko KM, Hamamori Y, et al. (2009). Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res 37: 5678-5689.
153. O'Connor TR, Laval J, (1991). Human cDNA expressing a functional DNA glycosylase excising 3-methyladenine and 7-methylguanine. Biochem Biophys Res Commun 176: 1170-1177.
154. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G, et al. (2009). ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 15: 7277-7290.
155. Patel AG, Sarkaria JN, Kaufmann SH, (2011). Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells. Proc Natl Acad Sci U S A 108: 3406-3411.
156. Patel AG, Flatten KS, Schneider PA, Dai NT, McDonald JS, Poirier GG, et al. (2012). Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes. J Biol Chem 287: 4198-4210.
157. Paull TT, Lee JH, (2005). The Mre11/Rad50/Nbs1 complex and its role as a DNA double-strand break sensor for ATM. Cell Cycle 4: 737-740.
158. Peasland A, Wang L-Z, Rowling E, Kyle S, Chen T, Hopkins A, et al. (2011). Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines. Br J Cancer 105: 372-381.
159. Pegg AE, (1990). Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129.
160. Penning TD, Zhu GD, Gandhi VB, Gong J, Liu X, Shi Y, et al. (2009). Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 52: 514-523.
161. Petermann E, Ziegler M, Oei SL, (2003). ATP-dependent selection between single nucleotide and long patch base excision repair. DNA Repair (Amst) 2: 1101-1114.
162. Pires IM, Olcina MM, Anbalagan S, Pollard JR, Reaper PM, Charlton PA, et al,. (2012). Targeting radiation-resistant hypoxic tumour cells through ATR inhibition. Br J Cancer 107: 291-299.
163. Plo I, Liao ZY, Barcelo JM, Kohlhagen G, Caldecott KW, Weinfeld M, et al. (2003). Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) 2: 1087-1100.
164. Plummer R, Lorigan P, Evans J, Steven N, Middleton M, Wilson R, et al. (2006). First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). J Clin Oncol 24 (18s): 8013.
165. Plummer R, Jones C, Middleton M, Wilson R, Evans J, Olsen A, et al. (2008). Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 14: 7917-7923.
166. Povirk LF, (1996). DNA damage and mutagenesis by radiomimetic DNA-cleaving agents: bleomycin, neocarzinostatin and other enediynes. Mutat Res 355: 71-89.
167. Price BD, Youmell MB, (1996). The phosphatidylinositol 3-kinase inhibitor wortmannin sensitizes murine fibroblasts and human tumor cells to radiation and blocks induction of p53 following DNA damage. Cancer Res 56: 246-250.
168. Rabik CA, Njoku MC, Dolan ME, (2006). Inactivation of O6-alkylguanine DNA alkyltransferase as a means to enhance chemotherapy. Cancer Treat Rev 32: 261-276.
169. Rainey MD, Charlton ME, Stanton RV, Kastan MB, (2008). Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res 68: 7466-7474.
170. Ranson M, Middleton MR, Bridgewater J, Lee SM, Dawson M, Jowle D, et al. (2006). Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 12: 1577-1584.
171. Reaper PM, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, et al. (2011). Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol 7: 428-430.
172. Rosenberg PS, Greene MH, Alter BP, (2003). Cancer incidence in persons with Fanconi anemia. Blood 101: 822-826.
173. Rosenzweig KE, Youmell MB, Palayoor ST, Price BD, (1997). Radiosensitization of human tumor cells by the phosphatidylinositol3-kinase inhibitors wortmannin and LY294002 correlates with inhibition of DNA-dependent protein kinase and prolonged G2-M delay. Clin Cancer Res 3: 1149-1156.
174. Rothkamm K, Kruger I, Thompson LH, Lobrich M, (2003). Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 23: 5706-5715.
175. Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG, (2010). PARP inhibition: PARP1 and beyond. Nat Rev Cancer 10: 293-301.
176. Ruf A, Menissier de Murcia J, de Murcia G, Schulz GE, (1996). Structure of the catalytic fragment of poly(ADP-ribose) polymerase from chicken. Proc Natl Acad Sci U S A 93: 7481-7485.
177. + binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 57: 3893-3900.
178. Russo AL, Kwon HC, Burgan WE, Carter D, Beam K, Weizheng X, et al. (2009). In vitro and in vivo radiosensitization of glioblastoma cells by the poly(ADP-ribose) polymerase inhibitor E7016. Clin Cancer Res 15: 607-612.
179. Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. (2008). Secondary mutations as a mechanism of cisplatin resistance in Brca2-mutated cancers. Nature 451: 1116-1120.
180. Saleh-Gohari N, Bryant HE, Schultz N, Parker KM, Cassel TN, Helleday T, (2005). Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 25: 7158-7169.
181. Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A, et al. (2011). Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: a phase I study. Invest New Drugs 30: 1493-1500.
182. Sarkaria JN, Busby EC, Tibbetts RS Roos P, Taya Y, Karnitz LM, Abraham RT, (1999). Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 59: 4375-4382.
183. Schlicker A, Peschke P, Bürkle A, Hahn EW, Kim JH, (1999). 4-Amino-1,8-naphthalimide: a novel inhibitor of poly(ADP-ribose) polymerase and radiation sensitizer. Int J Radiat 75: 91-100.
184. Schreiber V, Dantzer F, Ame JC, de Murcia G, (2006). Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol 7: 517-528.
185. Schultz N, Lopez E, Saleh-Gohari N, Helleday T, (2003). Poly(ADP-ribose) polymerase (PARP-1) has a controlling role in homologous recombination. Nucleic Acids Res 31: 4959-4964.
186. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, et al. (2011). Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 10: 1949-1958.
187. Shaheen FS, Znojek P, Fisher A, Webster M, Plummer R, Gaughan L, et al. (2011). Targeting the DNA double strand break repair machinery in prostate cancer. PLoS ONE 6: e20311.
188. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, et al. (2007). Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128: 157-170.
189. Sherr CJ, (1996). Cancer cell cycles. Science 274: 1672-1674.
190. Shi W, Feng Z, Zhang J, Gonzalez-Suarez I, Vanderwaal RP, Wu X, et al. (2010). The role of RPA2 phosphorylation in homologous recombination in response to replication arrest. Carcinogenesis 31: 994-1002.
191. Shibata A, Conrad S, Birraux J, Geuting V, Barton O, Ismail A, et al. (2011). Factors determining DNA double-strand break repair pathway choice in G2 phase. EMBO J 30: 1079-1092.
192. Shinohara ET, Geng L, Tan J, Chen H, Shir Y, Edwards E, et al. (2005). DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res 65: 4987-4992.
193. Shrivastav M, De Haro LP, Nickoloff JA, (2008). Regulation of DNA double-strand break repair pathway choice. Cell Res 18: 134-147.
194. Skalitzky DJ, Marakovits JT, Maegley KA, Ekker A, Yu X-H, Hostomsky Z, et al. (2003). Tricyclic benzimidazoles as potent PARP-1 inhibitors. J Med Chem 46: 210-213.
195. Smith LM, Willmore E, Austin CA, Curtin NJ, (2005). The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res 11: 8449-8457.
196. Sorensen CS, Hansen LT, Dziegielewski J, Syljuåsen RG, Lundin C, Bartek J, et al. (2005). The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol 7: 195-201.
197. Stiff T, O'Driscoll M, Rief N, Iwabuchi K, Lobrich M, Jeggo PA, (2004). ATM and DNA-PK function redundantly to phosphorylate H2AX after exposure to ionizing radiation. Cancer Res 64: 2390-2396.
198. Sung P, Klein H, (2006). Mechanism of homologous recombination: mediators and helicases take on regulatory functions. Nat Rev Mol Cell Biol 7: 739-750.
199. Suto MJ, Turner WR, Arundel-Suto CM, Werbel LM, Sebolt-Leopold JS, (1991). Dihydroisoquinolinones: the design and synthesis of a new series of potent inhibitors of poly(ADP-ribose) polymerase. Anticancer Drug Des 6: 107-117.
200. Swisher EM, Sakai W, Karlan BY, Wurz K, Urban N, Taniguchi T, (2008). Secondary Brca1 mutations in Brca1-mutated ovarian carcinomas with platinum resistance. Cancer Res 68: 2581-2586.
201. Tanaka T, Yamagami T, Oka Y, Nomura T, Sugiyama H, (1993). The scid mutation in mice causes defects in the repair system for both double-strand DNA breaks and DNA cross-links. Mutat Res 288: 277-280.
202. Taverna P, Liu L, Hwang HS, Hanson AJ, Kinsella TJ, Gerson SL, (2001). Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Res 485: 269-281.
203. Taverna P, Hwang HS, Schupp JE, Radivoyevitch T, Session NN, Reddy G, et al. (2003). Inhibition of base excision repair potentiates iododeoxyuridine- induced cytotoxicity and radiosensitization. Cancer Res 63: 838-846.
204. Taylor AM, Harnden DG, Arlett CF, Harcourt SA, Lehmann AR, Stevens S, et al. (1975). Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature 258: 427-429.
205. Tentori L, Turriziani M, Franco D, Serafino A, Levati L, Roy R, et al. (1999). Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia 13: 901-909.
206. Tentori L, Portarena I, Graziani G, (2002). Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol Res 45: 73-85.
207. Tentori L, Leonetti C, Scarsella M, Muzi A, Mazzon E, Vergati M, et al. (2006). Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma. FASEB J 20: 1709-1711.
208. Thomas HD, Calabrese CR, Batey MA, Canan S, Hostomsky Z, Kyle S, et al. (2007). Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial. Mol Cancer Ther 6: 945-956.
209. Thompson D, Duedal S, Kirner J, (2005). Cancer risks and mortality in heterozygous ATM mutation carriers. J Natl Cancer Inst 97: 813-822.
210. Thorslund T, McIlwraith MJ, Compton SA, Lekomtsev S, Petronczki M, Griffith JD, et al. (2010). The breast cancer tumor suppressor BRCA2 promotes the specific targeting of RAD51 to single-stranded DNA. Nat Struct Mol Biol 17: 1263-1265.
211. Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, et al. (2011). A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 18: 721-727.
212. Tsuzuki T, Sakumi K, Shiraishi A, Kawate H, Igarashi H, Iwakuma T, et al. (1996). Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. Carcinogenesis 17: 1215-1220.
213. Turner NC, Lord CJ, Iorns E, Brough R, Swift S, Elliott R, et al. (2008). Synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor. EMBO J 27: 1368-1377.
214. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. (2010). Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 376: 235-244.
215. Venkitaraman AR, (2002). Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108: 171-182.
216. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC, Durkacz BW, (2003). Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 63: 6008-6015.
217. Wagner JM, Kaufmann SH, (2010). Prospects for the use of ATR inhibitors to treat cancer. Pharmaceuticals 3: 1311-1334.
218. Wang L, Mason KA, Ang KK, Buchholz T, Valdecanas D, Mathur A, et al. (2012). MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs 30: 2113-2120.
219. Ward IM, Minn K, Chen J, (2004). UV-induced ataxia telangiectasia mutated and RAD3-related (ATR) activation requires replicative stress. J Biol Chem 279: 9677-9680.
220. Wedge SR, Porteous JK, Newlands ES, (1996). 3-Aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74: 1030-1036.
221. Weiss GJ, Gordon MS, Rosen LS, Savvides P, Ramanathan RK, Mendelson DS, et al. (2010). Final results from a phase 1 study of oral TRC102 (MethoxyamineHCl), an inhibitor of base-excision repair, to potentiate the activity of pemetrexedin patients with refractory cancer. J Clin Oncol 28 (15s): 2010 (suppl; abstr 2576).
222. Willmore E, de Caux S, Sunter NJ, Tilby MJ, Jackson GH, Austin CA, et al. (2004). A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood 103: 4659-4665.
223. Willmore E, Elliott SL, Mainou-Fowler T, Summerfield GP, Jackson GH, O'Neill F, et al. (2008). DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res 14: 3984-3992.
224. Wilson DM 3rd, Simeonov A, (2010). Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell Mol Life Sci 67: 3621-3631.
225. Xanthoudakis S, Smeyne RJ, Wallace JD, Curran T, (1996). The redox/DNA repair protein Ref-1 is essential for early embryonic development in mice. Proc Natl Acad Sci U S A 93: 8919-8923.
226. Zhang F, Ma J, Wu J, Ye L, Cai H, Xia B, et al. (2009). PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 19: 524-529.
227. Zhao Y, Thomas HD, Batey MA, Cowell IG, Richardson CJ, Griffin RJ, et al. (2006). Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res 66: 5354-5362.
228. Zhong Q, Chen CF, Li S, Chen Y, Wang CC, Xiao J, et al. (1999). Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science 285: 747-750.